Background: Paediatric Cushing’s disease (CD) is rare, but is associated with considerable morbidity and requires effective treatment. Control of hypercortisolaemia is recommended prior to definitive therapy by transsphenoidal pituitary surgery with selective adenomectomy. We describe a 6.2-year-old male with severe hypercortisolaemia and life-threatening complications of Cushing’s disease. Control of cortisol with metyrapone and ketoconazole was ineffective, and due to his deteriorating condition, the decision was taken to proceed to bilateral adrenalectomy. Methods: Low-dose IV infusion of etomidate, with dose titration according to serum cortisol levels, was administered. Results: Etomidate infusion (3.0 mg/h i.v.) decreased serum cortisol from 1,250 to 250 nmol/l within 24 h. Combined etomidate and hydrocortisone therapy was maintained to provide stable serum cortisol levels within the desired range for 12 days prior to successful bilateral adrenalectomy. Conclusion: In our experience, etomidate was effective and safe for short-term control of severe hypercortisolaemia in a severely ill child.

1.
Magiakou MA, Mastorakos G, Oldfield EH, Doppman JL, Cutler GB Jr, Nieman LK, Chrousos GP: Cushing’s syndrome in children and adolescence: presentation, diagnosis, and therapy. N Engl J Med 1994;331:629–636.
2.
Savage MO, Besser GM: Cushing’s disease in childhood. Trends Endocrinol Metab 1996;7:213–216.
3.
Verhelst A, Trainer PJ, Howlett TA, et al: Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin Endocrinol 1991;35:169–178.
4.
Fahlbusch R, Honegger J, Buchfelder M: Neurosurgical management of Cushing’s disease in children; in Savage MO, Bourguignon JP, Grossman AB (eds): Frontiers of Paediatric Neuroendocrinology. Oxford, Blackwell Scientific Publications, 1994, pp 68–72.
5.
Storr HL, Plowman PN, Carroll PV, Francois I, Krassass G, Afshar F, Besser GM, Grossman AB, Savage MO: Clinical and endocrine responses to pituitary radiotherapy in pediatric Cushing’s disease: an effective second-line treatment. J Clin Endocrinol Metab 2003;88:34–37.
6.
Allolio B, Stuttmann R, Fischer H, Leonharp W, Winkelmann W: Long-term etomidate, and adrenocortical suppression. Lancet 1983; ii:626.
7.
Schulte HM, Benker G, Reinwein D, Sippell WG, Allolio B: Infusion of low-dose etomidate: correction of hypercortisolemia in patients with Cushing’s syndrome and dose-response relationship in normal subjects. J Clin Endocrinol Metab1990;70:1426–1430.
8.
Gartner R, Albrecht M, Muller OA: Effect of etomidate on hypercortisolism due to ectopic ACTH production. Lancet 1986;i:275.
9.
Drake WM, Perry LA, Hinds CJ, Lowe DG, Reznek RH, Besser GM: Emergency and prolonged use of intravenous etomidate to control hypercortisolemia in a patient with Cushing’s syndrome and peritonitis. J Clin Endocrinol Metab 1998;83:3542–3544.
10.
Rockall AG, Sohaib SA, Evans D, Kaltsas G, Isidori AM, Monson JP, Besser GM, Grossman AB, Reznek RH: Hepatic steatosis in Cushing’s syndrome: a radiological assessment using computed tomography. Eur J Endocrinol 2003;149:543–548.
11.
Newell-Price J, Trainer PJ, Besser GM, Grossman AB: The diagnosis and differential diagnosis of Cushing’s and pseudo-Cushing’s states. Endocr Rev 1998;19:647–672.
12.
Sonino N, Boscaro M, Paoletta A, Mantero F, Ziliotto D: Ketoconazole treatment in Cushing’s syndrome: experience in 34 patients. Clin Endocrinol 1991;35:347–352.
13.
Krakoff J, Koch CA, Calis KA, Alexander RH, Nieman LK: Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing’s syndrome. J Clin Endocrinol Metab 2001;86:4104–4108.
14.
Ledingham IM, Watt I: Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1983;i:1270.
15.
Watt I, Ledingham IM: Mortality amongst multiple trauma patients admitted to an intensive therapy unit. Anaesthesia 1984;39:973–981.
16.
Klausen NO, Moelgaard J, Ferguson AH, Kaalund Jensen J, Larsen C, Paaby P: Negative synacthen test during etomidate infusion. Lancet 1983;i:848.
17.
Lambert A, Mitchell R, Frost J, Ratcliffe JG, Roberts WR: Direct in vitro inhibition of adrenal steroidogenesis by etomidate. Lancet 1983;ii:1085–1086.
18.
Lamberts SW, Bons EG, Bruining HA, de Jong FH: Differential effects of the imidazole derivatives etomidate, ketoconazole and miconazole and of metyrapone on the secretion of cortisol and its precursors by human adrenocortical cells. J Pharmacol Exp Ther 1987;240:259–264.
19.
Allolio B, Dorr H, Stuttmann DK, Engelhardt D, Winkelmann W: Effect of a single bolus of etomidate upon eight major corticosteroid hormones and plasma ACTH. Clin Endocrinol 1985;21:281–286.
20.
Dorr HG, Kühnle U, Holthausen H, Bidlingmaier F, Knorr D: Etomidate: A selective adrenocortical 11-beta-hydroxylase inhibitor. Klin Wochenschr 1984;62:1011–1013.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.